VOICED : Alemanas Bayer y CureVac unen sus fuerzas para desarrollar vacuna contra coronavirus

Bayer and CureVac have partnered to develop a COVID-19 vaccine. Bayer will assist in production and marketing. CureVac's vaccine, using mRNA technology, is in the final clinical trial phase and aims for market release this year. Unlike other vaccines, it remains stable at refrigerator temperatures, easing distribution. The European Commission has pre-ordered 405 million doses.

What is the main focus of the collaboration between Bayer and CureVac?

• Creating a COVID-19 vaccine

• Enhancing COVID-19 prevention guidelines

• Developing a new COVID-19 treatment

• Improving COVID-19 testing methods

What phase are CureVac's clinical trials currently in?

• Third and final phase

• Pre-clinical phase

• First phase

• Second phase

What is a key advantage of CureVac's mRNA vaccine compared to others?

• It requires no refrigeration

• It can be stored at room temperature

• It is effective against all COVID-19 variants

• It remains stable at refrigerator temperatures for three months

Which technology does CureVac's vaccine use?

• mRNA

• Inactivated virus

• Viral vector

• Protein subunit

How many doses has the European Commission agreed to purchase from CureVac?

• 500 million

• 405 million

• 200 million

• 100 million